Jim Cramer: 'Hold On' To Builders FirstSource, 'Here's The Problem' With Viking Therapeutics

On CNBC's “Mad Money Lightning Round,” Jim Cramer said Vertex Pharmaceuticals Incorporated VRTX is “great.”

On Aug. 1, Vertex Pharmaceuticals reported second-quarter revenues of $2.65 billion, almost in line with the consensus of estimate of $2.66 billion. Vertex raised its 2024 product revenue guidance from $10.55 billion-$10.75 billion to $10.65 billion-$10.85 billion.

When asked about Serve Robotics Inc. SERV, he said, “We're not recommending companies that lose a ton of money because it's just not the right time.”

On Aug. 28, Serve Robotics announced closing of $20 million private placement & warrant exercise.

Builders FirstSource, Inc. BLDR can “go higher,” Cramer said, “This is precisely the kind of stock you should be buying at this stage in the cycle. Hold on.”

On Aug. 6, Builders FirstSource reported second-quarter adjusted earnings per share of $3.50, beating the street view of $3.02. Quarterly sales of $4.456 billion missed the street view of $4.483 billion.

“Here's the problem: it costs so much money to build the factories, they're going to have to get a takeover to be able to do that,” Cramer said about Viking Therapeutics, Inc. VKTX.

On July 24, Viking Therapeutics reported better-than-expected second-quarter EPS results.

Price Action:

• Serve Robotics shares fell 1.3% to settle at $9.35 on Wednesday.
• Builders FirstSource shares fell 1% to close at $172.90.
• Vertex Pharmaceuticals shares gained 2% to close at $489.73.
• Viking Therapeutics shares fell 0.4% to settle at $61.16 on Wednesday.

Read Next:

• Wall Street’s Most Accurate Analysts Spotlight On 3 Materials Stocks Delivering High-Dividend Yields